People · Operator
Named in public records as an officer, director or promoter · active 2009–2024 · Biotechnology, Other Health Care, Other, Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Allogene Therapeutics, Inc. | — | Biotechnology | Growth/Late | $411.8M | $17.5B | 2018 |
| ByHeart, Inc. | — | Other Health Care | Series C | $378.4M | $493.6M | 2021 |
| Kronos Bio, Inc. | — | Biotechnology | Series D+ | $123.0M | $4.3B | 2018 |
| IconOVir Bio, Inc. | — | Biotechnology | Series C | $97.2M | $271.4M | 2020 |
| Kite Pharma, Inc. | — | Biotechnology | Series C | $79.1M | $2.0B | 2011 |
| Velcera, Inc. | — | Other | Series B | $66.0M | $599.0M | 2010 |
| Arno Therapeutics, Inc | — | Pharmaceuticals | Series B | $54.9M | $153.4M | 2010 |
| Capricor Therapeutics, Inc. | — | Biotechnology | Series B | $51.9M | $147.2M | 2009 |
| Kirax Corp | — | Pharmaceuticals | Series A | $7.0M | $25.6M | 2012 |
| Veterinary Prime, Inc. | — | Other | Series A | $4.3M | $64.8M | 2017 |
Joshua A. Kazam at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Joshua A. Kazam on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.